May 2017

Simvastatin and ARDS Outcome

Screen Shot 2017-05-18 at 11.12.26.png

Simvastatin was found to be cost-effective for the treatment of ARDS, being associated with both a significant QALY gain and a cost saving. There was no significant reduction in mortality at 12 months,